Navigation Links
XTL Biopharmaceuticals Implements Restructuring Plan
Date:12/8/2008

VALLEY COTTAGE, N.Y., Dec. 8 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that it is restructuring its operations following the failure of the Bicifadine Phase 2b clinical trial. The company is terminating the employment of 9 employees, representing 75% of its workforce. The remaining employees will be responsible for seeking potential assets or a company to merge into XTL, or for assisting in the liquidation and/or disposition of XTL's assets.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future business prospects, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. It is possible that we will not be able to find a buyer for the assets or a merger partner. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com . The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... ... largest Asian exhibitions for analytical and scientific instruments. This year’s symposium, organized by ... Approaches in Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, ... modular downlights designed to stay tightly sealed and perform efficiently for years. The ... wet location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; ...
(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica ... biotic and abiotic factors. During this educational webinar, participants will learn about the ... as gain a better understanding of how genomics is important for coffee breeding ...
(Date:8/14/2017)... ... 14, 2017 , ... Every year, millions of dollars are ... community have recently come together to address this antibody crisis and develop standards ... , The team at Thermo Fisher Scientific has arranged for an ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):